Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. LID - 10.1183/16000617.0057-2017 [doi] LID - 170057.
12. Kang J, Chung MP, Park MS, Oh IJ, Lee HB, Kim YW, Park JS, Uh ST, Kim YS, Jegal Y, Song JW: Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study.
13. Li R, Jia Y, Kong X, Nie Y, Deng Y, Liu Y: Novel drug delivery systems and disease models for pulmonary fibrosis.
14. Rong L, Xie M, Jiang M, Qiu H, Kong LA-O: A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database. LID - 10.1111/bcp.15673 [doi].
15. Böhm R, von Hehn L, Herdegen T, Klein HJ, Bruhn O, Petri H, Höcker J: OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications.
16. Evans SJ, Waller Pc Fau - Davis S, Davis S: Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports.
17. Rothman KJ, Lanes S Fau - Sacks ST, Sacks ST: The reporting odds ratio and its advantages over the proportional reporting ratio.
18. Justet A, Klay D, Porcher RA-O, Cottin VA-O, Ahmad K, Molina Molina M, Nunes H, Reynaud-Gaubert M, Naccache JM, Manali E, et al: